CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical and Experimental Rheumatology

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 22691208
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis

  2011cited by this paper
• Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis.

  2009cited by this paper
• Role of connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein‐1 in skin fibrosis

  2009cited by this paper
• Increased serum fractalkine in systemic sclerosis. Down-regulation by prostaglandin E1.

  2008cited by this paper
• CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study.

  2008cited by this paper
• Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis.

  2008cited by this paper
• Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.

  2007cited by this paper
• Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?

  2007cited by this paper
• Endothelin‐1 serum levels correlate with MCP‐1 but not with homocysteine plasma concentration in patients with systemic sclerosis

  2006cited by this paper
• Vasoactive therapies in systemic sclerosis.

  2006cited by this paper
• Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.

  2006cited by this paper
• The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis.

  2005cited by this paper
• The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn).

  2005cited by this paper
• Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma.

  2003cited by this paper
• Gene expression in bronchoalveolar lavage cells from scleroderma patients.

  2002cited by this paper
• Murine Sclerodermatous Graft-Versus-Host Disease, a Model for Human Scleroderma: Cutaneous Cytokines, Chemokines, and Immune Cell Activation1

  2002cited by this paper
• Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis.

  2001cited by this paper
• Elevated serum levels of soluble L-selectin in patients with systemic sclerosis declined after intravenous injection of lipo-prostaglandin E1.

  2001cited by this paper
• Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.

  2001cited by this paper
• Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis.

  2000cited by this paper
• Hemostasis and fibrinolysis in patients with intermittent claudication: effects of prostaglandin E1.

  2000cited by this paper
• Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis.

  1999cited by this paper
• Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis

  1999cited by this paper
• Abnormalities of adhesion molecules and chemokines in scleroderma.

  1999cited by this paper
• Novel roles for chemokines and fibroblasts in interstitial fibrosis.

  1998cited by this paper
• Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis.

  1997cited by this paper
• Effects of prostaglandin E1 on cultured dermal fibroblasts from normal and hypertrophic scarred skin.

  1997cited by this paper
• Differential CC chemokine-induced enhancement of T helper cell cytokine production.

  1997cited by this paper
• Actions of the chemotactic cytokines MCP‐1, MCP‐2, MCP‐3, RANTES, MIP‐1α and MIP‐1β on human monocytes

  1995cited by this paper
• Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes.

  1995cited by this paper
• Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

  1995cited by this paper
• Potent inhibition of leukotriene (LT) B4 release from human polymorphonuclear leukocytes (PMN) by the PGE1-analogue OP-1206.

  1988cited by this paper
• Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

  1988cited by this paper
• Potent inhibition of superoxide anion generation by PGE1 and the PGE1 analogue OP-1206 in human PMN's--unrelated to its antiplatelet PGI2-like activity.

  1987cited by this paper
• Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis.

  1981cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma).

  1980cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

  1980cited by this paper

• Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT2BR) in murine models and ex vivo models of scleroderma skin

  2025influential citation
• Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs

  2025cites this paper
• Sclerotic GVHD and Scleroderma Share Dysregulated Gene Expression that is Ameliorated by EREG Therapeutic Antibody.

  2025cites this paper
• Common biomarkers of idiopathic pulmonary fibrosis and systemic sclerosis based on WGCNA and machine learning

  2025cites this paper
• CXCL9 and CXCL10 support the exacerbated humoral response in recovered COVID-19 patients who developed acute respiratory distress syndrome by promoting plasma cell differentiation, whereas CXCL9 also induces CD40L and CXCR3 upregulation on T helper cells

  2025cites this paper
• Predictors of Remission or Combined Remission and Low Disease Activity in Rheumatoid Arthritis Patients in Taiwan: A Prospective Cohort Study

  2024cites this paper
• Human hypofunctional NCF1 variants promote pulmonary fibrosis in the bleomycin-induced mouse model and patients with systemic sclerosis via expansion of SPP1+ monocytes-derived macrophages

  2024cites this paper
• Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc

  2023cites this paper
• RANTES (CCL5) in Patients With Geographic Atrophy Age-Related Macular Degeneration

  2023cites this paper
• S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin

  2023cites this paper
• CC chemokines family in fibrosis and aging: from mechanisms to therapy.

  2023cites this paper
• Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review

  2023cites this paper
• Molecular Mechanisms Behind the Role of Plasmacytoid Dendritic Cells in Systemic Sclerosis

  2023cites this paper
• Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation

  2023cites this paper
• Increased L-Selectin on Monocytes Is Linked to the Autoantibody Profile in Systemic Sclerosis

  2022cites this paper
• Pyroptosis executor gasdermin D plays a key role in scleroderma and bleomycin-induced skin fibrosis

  2022influential citation
• Human Cytomegalovirus and Human Herpesvirus 6 Coinfection of Dermal Fibroblasts Enhances the Pro-Inflammatory Pathway Predisposing to Fibrosis: The Possible Impact on Systemic Sclerosis

  2022cites this paper
• PET/CT and inflammatory mediators in systemic sclerosis-associated interstitial lung disease

  2022cites this paper
• The Role of Atypical Chemokine Receptor D6 (ACKR2) in Physiological and Pathological Conditions; Friend, Foe, or Both?

  2022cites this paper
• Pyroptosis executor gasdermin D plays a key role in scleroderma and bleomycin-induced skin fibrosis

  2022cites this paper
• Sex Differences in RANTES (CCL5) in Patients With Intermediate Age-Related Macular Degeneration (AMD) and Controls With no AMD

  2022cites this paper
• Risk of major adverse cardiovascular events among patients with rheumatoid arthritis after initial CT-based diagnosis and treatment

  2020cites this paper
• Role of placental inflammatory mediators and growth factors in patients with rheumatic diseases with a focus on systemic sclerosis

  2020cites this paper
• Large‐Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis

  2020cites this paper
• Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis

  2020cites this paper
• Impact of Human Cytomegalovirus and Human Herpesvirus 6 Infection on the Expression of Factors Associated with Cell Fibrosis and Apoptosis: Clues for Implication in Systemic Sclerosis Development

  2020cites this paper
• Transgenic interleukin 11 expression causes cross-tissue fibro-inflammation and an inflammatory bowel phenotype in mice

  2020cites this paper
• Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis

  2019cites this paper
• Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis

  2019cites this paper
• Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature

  2019cites this paper
• Interleukin 11 expression causes murine inflammatory bowel disease

  2019cites this paper
• Fibrosis and Immune Dysregulation in Systemic Sclerosis

  2018cites this paper
• Rôle de la réponse immunitaire de type 2 dans la réparation tissulaire : du concept au modèle pratique de la sclérodermie systémique

  2018cites this paper
• Corticosteroid inhibits chemokines production in systemic sclerosis patients

  2017cites this paper
• Dual endothelin receptor antagonists contrast the effects induced by endothelin-1 on cultured human microvascular endothelial cells.

  2017cites this paper
• Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment

  2017cites this paper
• Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta

  2017cites this paper
• Chemokines in systemic sclerosis.

  2017cites this paper
• Cutaneous Fibrosis and Normal Wound Healing

  2017cites this paper
• Immune-Mediated Repair: A Matter of Plasticity

  2017cites this paper
• Angiostatic and Angiogenic Chemokines in Systemic Sclerosis: An Overview

  2017cites this paper
• B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis

  2017cites this paper
• Capillaroscopic findings and vascular biomarkers in systemic sclerosis: Association of low CD40L levels with late scleroderma pattern.

  2016cites this paper
• Avaliação do perfil de citocinas e quimiocinas em pacientes com esclerose sistêmica: correlação com manifestações clínicas e com resposta ao tratamento

  2016cites this paper
• Assessing pain and inflammation in arthritis using novel imaging methods

  2016cites this paper
• Current perspectives on the immunopathogenesis of systemic sclerosis

  2016cites this paper
• Lung Function, Respiratory Muscle Strength, and Thoracoabdominal Mobility in Women With Fibromyalgia Syndrome

  2016cites this paper
• Astragalus polysaccharide suppresses excessive collagen accumulation in a murine model of bleomycin-induced scleroderma.

  2015cites this paper
• Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

  2015cites this paper
• Systemic sclerosis

  2015cites this paper
• Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis.

  2015cites this paper
• Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.

  2015cites this paper
• Cytokines in the immunopathology of systemic sclerosis

  2015cites this paper
• Molecular Biomarkers in Interstitial Lung Diseases

  2014cites this paper
• Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy

  2014cites this paper
• Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis

  2014cites this paper
• Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial

  2014cites this paper
• Systemic Sclerosis, Scleroderma

  2014cites this paper
• IL-13 signaling via IL-13Rα2 triggers TGF-β1-dependent allograft fibrosis

  2013cites this paper
• Systemic sclerosis: a critical digest of the recent literature.

  2013cites this paper
• Endothelial cells recruit macrophages and contribute to a fibrotic milieu in bleomycin lung injury.

  2013cites this paper
• Novel Coronary Atherothrombosis Genes Identified By Blood Cell Transcriptomics

  2013cites this paper
• Understanding itch in systemic sclerosis in order to improve patient quality of life.

  2013cites this paper
• Augmented in vitro expression of CCL2 by peripheral blood mononuclear cells is associated with the presence of interstitial lung disease in patients with systemic sclerosis

  2013cites this paper
• A systematic overview on the use and relevance of capillaroscopy in systemic sclerosis

  2013cites this paper
• Chemoattractant receptors in drug discovery: FPR2 and CCR2-two potential targets

  2012cites this paper